BioNTech SE

128.67+7.15+5.88%Vol 3.71M1Y Perf 207.72%
Apr 13th, 2021 15:35 DELAYED
BID128.58 ASK128.71
Open125.00 Previous Close121.52
Pre-Market- After-Market-
 - -%  - -
Target Price
107.83 
Analyst Rating
Moderate Buy 2.14
Potential %
-16.42 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.28
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★ —    60.83
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap30.98B 
Earnings Rating
Price Range Ratio 52W %
97.52 
Earnings Date
10th May 2021

Today's Price Range

124.77130.81

52W Range

37.00131.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.73%
1 Month
17.66%
3 Months
18.43%
6 Months
30.67%
1 Year
207.72%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BNTX128.677.15005.88
AAPL134.453.21002.45
GOOG2 274.0119.22000.85
MSFT258.422.51000.98
XOM55.730.23000.41
WFC39.80-0.9700-2.38
JNJ159.71-1.9300-1.19
FB311.15-0.3900-0.13
GE13.51-0.0800-0.59
JPM154.54-1.4100-0.90
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.571.87428.07
Q03 2020-0.46-1.03-123.91
Q02 2020-0.29-0.42-44.83
Q01 2020-0.30-0.2613.33
Q04 2019-0.19-0.29-52.63
Q03 2019-0.21-0.1623.81
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date10th May 2021
Estimated EPS Next Report2.66
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume3.71M
Shares Outstanding240.79M
Trades Count46.01K
Dollar Volume132.94M
Avg. Volume1.95M
Avg. Weekly Volume2.35M
Avg. Monthly Volume1.69M
Avg. Quarterly Volume1.79M

BioNTech SE (NASDAQ: BNTX) stock closed at 121.52 per share at the end of the most recent trading day (a -0.51% change compared to the prior day closing price) with a volume of 1.62M shares and market capitalization of 30.98B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1310 people. BioNTech SE CEO is Ugur Sahin.

The one-year performance of BioNTech SE stock is 207.72%, while year-to-date (YTD) performance is 49.07%. BNTX stock has a five-year performance of %. Its 52-week range is between 37 and 131, which gives BNTX stock a 52-week price range ratio of 97.52%

BioNTech SE currently has a PE ratio of 988.60, a price-to-book (PB) ratio of 16.98, a price-to-sale (PS) ratio of 52.94, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 0.98%, a ROC of -50.61% and a ROE of 1.63%. The company’s profit margin is 15.08%, its EBITDA margin is -225.70%, and its revenue ttm is $554.40 Million , which makes it $2.30 revenue per share.

Of the last four earnings reports from BioNTech SE, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $2.66 for the next earnings report. BioNTech SE’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for BioNTech SE is Moderate Buy (2.14), with a target price of $107.83, which is -16.42% compared to the current price. The earnings rating for BioNTech SE stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioNTech SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioNTech SE has a Buy technical analysis rating based on Technical Indicators (ADX : 14.47, ATR14 : 6.18, CCI20 : 141.32, Chaikin Money Flow : 0.27, MACD : -2.19, Money Flow Index : 78.52, ROC : 29.21, RSI : 37.29, STOCH (14,3) : 93.52, STOCH RSI : 0.79, UO : 67.36, Williams %R : -6.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioNTech SE in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (42.86 %)
2 (28.57 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (57.14 %)
5 (71.43 %)
3 (42.86 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.14
Moderate Buy
2.43
Moderate Buy
1.86

BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

CEO: Ugur Sahin

Telephone: +49 613190840

Address: An der Goldgrube 12, Mainz D-55131, , DE

Number of employees: 1 310

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

60%40%

Bearish Bullish

61%39%

News

Stocktwits